These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 34036576)
1. Non-transplantable cord blood units as a source for adoptive immunotherapy of leukaemia and a paradigm of circular economy in medicine. Koukoulias K; Papadopoulou A; Kouimtzidis A; Papayanni PG; Papaloizou A; Sotiropoulos D; Yiangou M; Costeas P; Anagnostopoulos A; Yannaki E; Kaloyannidis P Br J Haematol; 2021 Jul; 194(1):158-167. PubMed ID: 34036576 [TBL] [Abstract][Full Text] [Related]
2. A single bout of dynamic exercise enhances the expansion of MAGE-A4 and PRAME-specific cytotoxic T-cells from healthy adults. LaVoy EC; Bollard CM; Hanley PJ; Blaney JW; O'Connor DP; Bosch JA; Simpson RJ Exerc Immunol Rev; 2015; 21():144-53. PubMed ID: 25826370 [TBL] [Abstract][Full Text] [Related]
3. Clinical Grade Production of Wilms' Tumor-1 Loaded Cord Blood-Derived Dendritic Cells to Prevent Relapse in Pediatric AML After Cord Blood Transplantation. Plantinga M; Lo Presti V; de Haar CG; Dünnebach E; Madrigal A; Lindemans CA; Boelens JJ; Nierkens S Front Immunol; 2020; 11():559152. PubMed ID: 33101274 [TBL] [Abstract][Full Text] [Related]
4. PRAME peptide-specific CD8 Matko S; Manderla J; Bonsack M; Schmitz M; Bornhauser M; Tonn T; Odendahl M Eur J Immunol; 2018 Aug; 48(8):1400-1411. PubMed ID: 29738081 [TBL] [Abstract][Full Text] [Related]
5. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study. Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696 [TBL] [Abstract][Full Text] [Related]
6. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Weber G; Gerdemann U; Caruana I; Savoldo B; Hensel NF; Rabin KR; Shpall EJ; Melenhorst JJ; Leen AM; Barrett AJ; Bollard CM Leukemia; 2013 Jul; 27(7):1538-47. PubMed ID: 23528871 [TBL] [Abstract][Full Text] [Related]
7. Ex vivo specific induction of CD8 positive anti-leukemia cytotoxic lymphocytes from umbilical cord blood. Tan H; Liu X; Ye X Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):129-33. PubMed ID: 17490538 [TBL] [Abstract][Full Text] [Related]
8. Targeting of the WT1 Dagvadorj N; Deuretzbacher A; Weisenberger D; Baumeister E; Trebing J; Lang I; Köchel C; Kapp M; Kapp K; Beilhack A; Hünig T; Einsele H; Wajant H; Grigoleit GU Cancer Immunol Immunother; 2017 Mar; 66(3):319-332. PubMed ID: 27896368 [TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro]. Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063 [TBL] [Abstract][Full Text] [Related]
10. Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy. Weber G; Caruana I; Rouce RH; Barrett AJ; Gerdemann U; Leen AM; Rabin KR; Bollard CM Clin Cancer Res; 2013 Sep; 19(18):5079-91. PubMed ID: 23838315 [TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381 [TBL] [Abstract][Full Text] [Related]
12. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate. Goddard RV; Prentice AG; Copplestone JA; Kaminski ER Clin Exp Immunol; 2001 Oct; 126(1):16-28. PubMed ID: 11678895 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Acute Leukemias: Implications and Perspectives Using Wt1 Antigen. Cebinelli GC; DE Sousa Pereira N; Sena MM; DE Oliveira CE; Fujita TC; DA Rocha SP; DE Abreu Oliveira FJ; Marinello PC; Watanabe MA Anticancer Res; 2016 Aug; 36(8):3795-802. PubMed ID: 27466479 [TBL] [Abstract][Full Text] [Related]
15. Wilms' tumor 1-specific cytotoxic T lymphocytes can be expanded from adult donors and cord blood. Krishnadas DK; Stamer MM; Dunham K; Bao L; Lucas KG Leuk Res; 2011 Nov; 35(11):1520-6. PubMed ID: 21774984 [TBL] [Abstract][Full Text] [Related]
16. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Micklethwaite KP; Savoldo B; Hanley PJ; Leen AM; Demmler-Harrison GJ; Cooper LJ; Liu H; Gee AP; Shpall EJ; Rooney CM; Heslop HE; Brenner MK; Bollard CM; Dotti G Blood; 2010 Apr; 115(13):2695-703. PubMed ID: 20110422 [TBL] [Abstract][Full Text] [Related]
17. Cord blood-derived T cells allow the generation of a more naïve tumor-reactive cytotoxic T-cell phenotype. Kwoczek J; Riese SB; Tischer S; Bak S; Lahrberg J; Oelke M; Maul H; Blasczyk R; Sauer M; Eiz-Vesper B Transfusion; 2018 Jan; 58(1):88-99. PubMed ID: 29023759 [TBL] [Abstract][Full Text] [Related]
18. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Mutis T; Verdijk R; Schrama E; Esendam B; Brand A; Goulmy E Blood; 1999 Apr; 93(7):2336-41. PubMed ID: 10090944 [TBL] [Abstract][Full Text] [Related]
19. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels WS; Jäger E; Bader P Leukemia; 2009 Sep; 23(9):1634-42. PubMed ID: 19357702 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of Heme Oxygenase-1 Activity Enhances Wilms Tumor-1-Specific T-Cell Responses in Cancer Immunotherapy. Schillingmann DA; Riese SB; Vijayan V; Tischer-Zimmermann S; Schmetzer H; Maecker-Kolhoff B; Blasczyk R; Immenschuh S; Eiz-Vesper B Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30678050 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]